Project Grant R33DA062217
Award Date 9/1/26
Completion Date 8/30/30
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $296,460 under NIDA's Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, for a research project examining housing stability and overdose prevention among people transitioning from shelter into housing. The award funds a prospective longitudinal cohort study following individuals as they move out of shelter into housing, with one-year follow-up tracking substance use outcomes (non-fatal...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $870,407 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on pre-release Medicaid effects on youth experiences related to substances (PRIME Years). The project addresses barriers to behavioral health service access for youth ages 16–25 following incarceration, a population with 36–84% prevalence of substance use history. The research examines Medicaid...
- The National Institute on Drug Abuse awarded The General Hospital Corporation (Massachusetts General Hospital) $453,750 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026. The award funds a mixed-methods examination of adolescent overdose and return to high-risk drug use after inpatient addiction treatment. The research leverages an existing longitudinal dataset of adolescents aged 12–19 followed for 12 months after treatment discharge, 52 percent of whom...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $1,593,298 under Project Grant R01DA066715 on July 1, 2026, to evaluate health impacts of municipal interventions addressing homelessness and opioid use disorder. The recipient will characterize longitudinal trends in overdose, health service use, and housing engagement among people experiencing homelessness from 2015 through 2024 across major policy actions; assess associations between homelessness programs and...
- The National Institute on Drug Abuse awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $598,000 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop machine-learning methods for detecting spatiotemporal change points in illicit drug supply composition and their correlation with overdose mortality trends. The recipient will apply correlated anomaly detection models, including Gaussian process subset scanning and...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $2.67 million on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and implement LINK, a system-wide informatics intervention designed to optimize medications for opioid use disorder (MOUD) and pre-exposure prophylaxis for HIV (PrEP) utilization and reduce missed opportunities to prevent opioid overdose and HIV infection. LINK comprises two integrated components: LINK2CARE, a...
- Federal Grant Award Summary Boston Medical Center Corporation received a $356,630 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 1, 2025, with completion scheduled for August 31, 2027. The grant supports immune profiling research investigating how drug abuse impacts antibody responses in people living with HIV (PLWH), particularly among people who use substances and live with HIV (PWUSH). The...
- The Centers for Disease Control and Prevention awarded a $1.397 million cooperative agreement to Boston Medical Center Corporation on September 30, 2025, to engage overdose survivors with the SafeSpot Hotline for secondary overdose prevention under the Injury Prevention and Control Research and State and Community Based Programs (CFDA 93.136). The cooperative agreement runs through September 29, 2030, with place of performance in Massachusetts. The award funds activities designed to reach...
- The National Institute on Drug Abuse awarded Brigham & Women's Hospital $557,105 on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to design, implement, and evaluate community-wide Public Access Naloxone (PAN) programs in three Massachusetts communities: Cambridge, Chelsea, and Lynn. Under this R61 planning-phase grant, the recipient will rigorously assess existing PAN initiatives through qualitative and quantitative stakeholder input to identify challenges...
- The National Institute on Drug Abuse awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $618,725 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate fentanyl overdose-induced anhedonia and relapse risk. The research examines whether fentanyl overdose intensifies addiction cycles through alterations in reward processing. The project tests three specific aims: whether fentanyl overdose leads to development or...